Tisotumab vedotin-tftv may now be given to patients with recurrent or metastatic cervical cancer, according to the FDA.
Approval Alert | Tisotumab Vedotin for Recurrent/Metastatic Cervical Cancer
Advertisement
Advertisement
Trending on CancerNetwork
1
Zurletrectinib Generates Responses in Advanced NTRK Fusion Solid Tumors
2
Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC
3
Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome
4
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars
5
